



REMARKS

Consideration of the above-captioned application in view of the above amendments and following remarks is requested. Claims 1, 3-4, 6, 13, 19, and 21-28 are now in the case. Claims 2 and 7 have been canceled. Claims 21 to 28 are newly added. Attached hereto is a marked-up version of the changes made to the specification and the claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made".

On the basis of the above amendments and remarks, Applicants believe that the claims are in condition for allowance. Applicants believe that no new matter has been added. In an effort to expedite prosecution and minimize filing costs Applicants have amended the claims. Applicants reserve the right to prosecute the original claims in another continuing application. Consideration of the application and its allowance are requested. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the application, the Examiner is invited to telephone the undersigned at (206) 442-6752.

Respectfully Submitted,



A handwritten signature in cursive ink, appearing to read "Robyn Adams".

Robyn Adams
Registration No. 44,495

Enclosures:

- Response to Restriction Requirement
- Petition and Fee for Extension of Time (in duplicate)
- Amendment Fee Transmittal (in duplicate)
- Version with Markings to Show Changes Made
- Postcard

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

Claims 2 and 7 are canceled

Claims 3,4, 6, and 13 are amended as follows:

3. (Amended) [The] An isolated polypeptide molecule [according to claim 1, wherein the polypeptide comprises] comprising residues 420 to 495 of SEQ ID NO:2.

4. (Amended) The isolated polypeptide molecule according to claim 3, wherein the polypeptide is selected from the group consisting of:

- a) a polypeptide molecule comprising residues 1 to 701 of SEQ ID NO:4;
- b) a polypeptide molecule comprising residues 208 to 495 of SEQ ID NO:2;
- c) a polypeptide molecule comprising residues 31 to 495 of SEQ ID NO:2;
- d) a polypeptide molecule comprising residues 1 to 495 of SEQ ID NO:2;
- e) a polypeptide molecule comprising residues 1 to 802 of SEQ ID NO:2; and
- f) a polypeptide molecule comprising residues 1 to 812 of SEQ ID NO:4.

6. (Amended) The isolated polypeptide molecule of claim [1] 3, [wherein at least nine contiguous amino acid residues of SEQ ID NO:2 or SEQ ID NO:4 are] operably linked via a peptide bond or polypeptide linker to a second polypeptide selected from the group consisting of maltose binding protein, an immunoglobulin constant region, and a polyhistidine tag.

[b)] 13. (Amended) [The] An isolated polypeptide made by the method of [claim 12]:

- a) constructing an expression vector comprising the following operably linked elements:

- i) a transcription promoter;
 - ii) a DNA segment encoding the polypeptide according to claim 3; and
 - iii) a transcription terminator;
- b) introducing the expression vector into a cultured cell whereby the cell expresses the polypeptide encoded by the DNA segment; and
- c) recovering the polypeptide.

Claims 21-28 are newly added.